Medivir

Medivir ROIC

The Return on Invested Capital (ROIC) of Medivir (MVIR.ST) as of Oct 27, 2026 is -35.69 %. In the previous year, Return on Invested Capital (ROIC) was -106.75 % — a change of -66.57% (higher).

ROIC

-35.69 %

YoY

-66.57%

Last updated:

Return on Invested Capital (ROIC) of Medivir is 2025 -35.69 % . Return on Invested Capital (ROIC) of Medivir was 2024 -106.75 % . It decreases by -66.57% higher compared to the previous year.

The Medivir ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-113.88 SEK
Jan 1, 2019
-54.06 SEK
Jan 1, 2020
-25.91 SEK
Jan 1, 2021
-22.45 SEK
Jan 1, 2022
-46.04 SEK
Jan 1, 2023
-40.99 SEK
Jan 1, 2024
-106.75 SEK
Jan 1, 2025
-35.69 SEK
The Medivir ROIC history
YEARROICYoY
-35.69 %-66.57%
-106.75 %+160.45%
-40.99 %-10.98%
-46.04 %+105.06%
-22.45 %-13.36%
-25.91 %-52.06%
-54.06 %-52.53%
-113.88 %+62.52%
-70.07 %-529.31%
16.32 %+215.21%
5.18 %-90.75%
56.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Return on Invested Capital (ROIC) of Medivir is -35.69 % in 2025.

Return on Invested Capital (ROIC) of Medivir changed from -106.75 % to -35.69 %, representing a -66.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Medivir since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Medivir with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medivir

All Key Metrics — Medivir